The Biden administration and government agencies continue to push Pfizer’s COVID-19 emergency use authorization product, Paxlovid, even with insufficient new trial data showing effectiveness in the current population.
Pfizer’s initial clinical trial for Paxlovid in 2021, which earned it an emergency use authorization (EAU) by the FDA, seemed quite promising. Results showed a relative risk reduction of progression to severe COVID-19 at 89 percent. But after the unapproved Pfizer product hit the market with its EAU in tow, real-world studies came out quite differently.
